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GeneticsMore than 150 different mycobacterial strains are known, of which only a few are consid-
ered pathogens in humans. The most pathogenic strains are the mycobacteria from the
Mycobacterium tuberculosis complex which cause the globally spread disease tuberculosis
and the Mycobacterium leprae and Mycobacterium lepromatosis strains that cause leprosy. In
addition to these well-knownmycobacteria, there are many non-tuberculous mycobacteria
(NTM) that are present in the environment and that seldom cause severe disease in healthy
individuals.
NTM infection can lead to severe disease in individuals with a failing immune system
due to a primary or secondary immunodeficiency. Mendelian susceptibility to mycobacte-
rial disease (MSMD) is a rare primary immunodeficiency characterized by a predisposition
to severe, sometimes lethal disease caused by otherwise poorly virulent NTM, as well as the
vaccine strain Mycobacterium bovis BCG. In these patients the mycobacterial infection is
often disseminated to various parts of the body and is difficult to treat. Interestingly, MSMD
patients do not, in general, develop pulmonary tuberculosis. MSMD is usually caused by
mutations in genes involved in the IL-12/IFN-c pathway, such as: IL12RB1 which encodes
the IL-12Rb1 chain of the IL-12 and the IL-23 receptor, IL12B which encodes the IL-12p40
subunit of IL-12 and IL-23, IFNGR1 and IFNGR2 which encode the two chains of the IFN-c
receptor, and STAT1 which encodes one of the proteins that signal in response to IFN-c.
The aim of our research is to identify the immunological and genetic defects in MSMD
patients. Hereto the integrity of the IL-12/IFN-c pathway is analysed in blood and isolated
cells from the patients, as well as expression of receptor chains on the membrane of the
cells. Mutations are subsequently identified by sequencing the genes involved. The effect
of novel mutations that lead to amino acid changes can be analysed in retroviral expression
models, as we have done for amongst others IL12RB1, IFNGR1 and IFNGR2.
To facilitate the analysis of variations identified by researchers around the world, dat-
abases have been set up that contain all reported MSMD patients and mutations (see for
instance: www.lovd.nl/IL12RB1). Thus far, just over 400 patients have been reported world-
wide with MSMD and this is probably only the tip of the iceberg. Also, other genes are still
expected to be found to cause MSMD; no genes have been reported so far in which muta-
tions specifically lead to susceptibility to tuberculosis.
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